A double blind comparison of piroxicam and enteric coated ASA in rheumatoid arthritis. A Cooperative Multicenter Canadian trial.
A double blind study compared piroxicam, 20 mg OD to enteric coated acetylsalicylic acid (EC ASA), 3.9-5.2 g daily in divided doses, in 145 patients with rheumatoid arthritis (RA). Both drugs improved the signs and symptoms of RA. Patients showed significantly better compliance with a once daily dosage regimen. Gastrointestinal side effect profiles were similar. The EC ASA group showed a higher frequency of tinnitis and more dropouts, while there were more skin reactions in the piroxicam group. Decreased hemoglobin and hematocrit values were more prevalent in the piroxicam group. Piroxicam proved to be an effective alternative therapy to EC ASA.
D000328:Adult; D000368:Aged; D000469:Alkaline Phosphatase / Q000378:metabolism; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000503:physiopathology; D001241:Aspirin / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D001806:Blood Urea Nitrogen; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006400:Hematocrit; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance; D010894:Piroxicam; D012649:Self Concept; D013608:Tablets, Enteric-Coated; D013843:Thiazines / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*
D006454:Hemoglobins; D013608:Tablets, Enteric-Coated; D013843:Thiazines; D010894:Piroxicam; D000469:Alkaline Phosphatase; D001241:Aspirin